Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 208

1.

Study of the effect of anti-rhGAA antibodies at low and intermediate titers in late onset Pompe patients treated with ERT.

Fernández-Simón E, Carrasco-Rozas A, Gallardo E, González-Quereda L, Alonso-Pérez J, Belmonte I, Pedrosa-Hernández I, Montiel E, Segovia S, Suárez-Calvet X, Llauger J, Mayos M, Illa I, Barba-Romero MA, Barcena J, Paradas C, Carzorla MR, Creus C, Coll-Cantí J, Díaz M, Domínguez C, Fernández-Torrón R, García-Antelo MJ, Grau JM, López de Munáin A, Martínez-García FA, Morgado Y, Moreno A, Morís G, Muñoz-Blanco MA, Nascimento A, Parajuá-Pozo JL, Querol L, Rojas R, Robledo-Strauss A, Rojas-Marcos Í, Salazar JA, Usón M, Díaz-Manera J.

Mol Genet Metab. 2019 Jul 23. pii: S1096-7192(18)30784-4. doi: 10.1016/j.ymgme.2019.07.013. [Epub ahead of print]

PMID:
31378569
2.

Identification of serum microRNAs as potential biomarkers in Pompe disease.

Carrasco-Rozas A, Fernández-Simón E, Lleixà MC, Belmonte I, Pedrosa-Hernandez I, Montiel-Morillo E, Nuñez-Peralta C, Llauger Rossello J, Segovia S, De Luna N, Suarez-Calvet X, Illa I; Pompe Spanish Study group, Díaz-Manera J, Gallardo E.

Ann Clin Transl Neurol. 2019 Jul;6(7):1214-1224. doi: 10.1002/acn3.50800. Epub 2019 Jun 12.

3.

Spanish Pompe registry: Baseline characteristics of first 49 patients with adult onset of Pompe disease.

Alonso-Pérez J, Segovia S, Domínguez-González C, Olivé M, Mendoza Grimón MD, Fernández-Torrón R, López de Munain A, Muñoz-Blanco JL, Ramos-Fransi A, Almendrote M, Illa I, Díaz-Manera J.

Med Clin (Barc). 2019 Jun 25. pii: S0025-7753(19)30346-X. doi: 10.1016/j.medcli.2019.03.036. [Epub ahead of print] English, Spanish.

PMID:
31253477
4.

Caveats and Pitfalls of SOX1 Autoantibody Testing With a Commercial Line Blot Assay in Paraneoplastic Neurological Investigations.

Ruiz-García R, Martínez-Hernández E, García-Ormaechea M, Español-Rego M, Sabater L, Querol L, Illa I, Dalmau J, Graus F.

Front Immunol. 2019 Apr 12;10:769. doi: 10.3389/fimmu.2019.00769. eCollection 2019.

5.

Correction: Absence of pathogenic mutations in CD59 in chronic inflammatory demyelinating polyradiculoneuropathy.

Duchateau L, Martín-Aguilar L, Lleixà C, Cortese A, Dols-Icardo O, Cervera-Carles L, Pascual-Goñi E, Diaz-Manera J, Callegari I, Franciotta D, Rojas-Garcia R, Illa I, Clarimon J, Querol L.

PLoS One. 2019 Apr 17;14(4):e0215784. doi: 10.1371/journal.pone.0215784. eCollection 2019.

6.

Clinical and laboratory features of anti-MAG neuropathy without monoclonal gammopathy.

Pascual-Goñi E, Martín-Aguilar L, Lleixà C, Martínez-Martínez L, Simón-Talero MJ, Díaz-Manera J, Cortés-Vicente E, Rojas-García R, Moga E, Juárez C, Illa I, Querol L.

Sci Rep. 2019 Apr 16;9(1):6155. doi: 10.1038/s41598-019-42545-8.

7.

Anti-Neurofascin-155 IgG4 antibodies prevent paranodal complex formation in vivo.

Manso C, Querol L, Lleixà C, Poncelet M, Mekaouche M, Vallat JM, Illa I, Devaux JJ.

J Clin Invest. 2019 Mar 14;129(6):2222-2236. doi: 10.1172/JCI124694.

8.

Absence of pathogenic mutations in CD59 in chronic inflammatory demyelinating polyradiculoneuropathy.

Duchateau L, Martín-Aguilar L, Lleixà C, Cortese A, Dols-Icardo O, Cervera-Carles L, Pascual-Goñi E, Diaz-Manera J, Calegari I, Franciotta D, Rojas-Garcia R, Illa I, Clarimon J, Querol L.

PLoS One. 2019 Feb 22;14(2):e0212647. doi: 10.1371/journal.pone.0212647. eCollection 2019. Erratum in: PLoS One. 2019 Apr 17;14(4):e0215784.

9.

Long-term safety and efficacy of eculizumab in generalized myasthenia gravis.

Muppidi S, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Nowak RJ, Andersen H, Casasnovas C, de Bleecker JL, Vu TH, Mantegazza R, O'Brien FL, Wang JJ, Fujita KP, Howard JF Jr; Regain Study Group.

Muscle Nerve. 2019 Jul;60(1):14-24. doi: 10.1002/mus.26447. Epub 2019 Mar 8.

10.

PDGF-BB serum levels are decreased in adult onset Pompe patients.

Fernández-Simón E, Carrasco-Rozas A, Gallardo E, Figueroa-Bonaparte S, Belmonte I, Pedrosa I, Montiel E, Suárez-Calvet X, Alonso-Pérez J, Segovia S, Nuñez-Peralta C, Llauger J, Mayos M, Illa I; Spanish Pompe Study Group, Díaz-Manera J.

Sci Rep. 2019 Feb 14;9(1):2139. doi: 10.1038/s41598-018-38025-0.

11.

Muscle MRI in a large cohort of patients with oculopharyngeal muscular dystrophy.

Alonso-Jimenez A, Kroon RHMJM, Alejaldre-Monforte A, Nuñez-Peralta C, Horlings CGC, van Engelen BGM, Olivé M, González L, Verges-Gil E, Paradas C, Márquez C, Garibaldi M, Gallano P, Rodriguez MJ, Gonzalez-Quereda L, Dominguez Gonzalez C, Vissing J, Fornander F, Eisum AV, García-Sobrino T, Pardo J, García-Figueiras R, Muelas N, Vilchez JJ, Kapetanovic S, Tasca G, Monforte M, Ricci E, Gomez MT, Bevilacqua JA, Diaz-Jara J, Zamorano II, Carlier RY, Laforet P, Pelayo-Negro A, Ramos-Fransi A, Martínez A, Marini-Bettolo C, Straub V, Gutiérrez G, Stojkovic T, Martín MA, Morís G, Fernández-Torrón R, Lopez De Munaín A, Cortes-Vicente E, Querol L, Rojas-García R, Illa I, Diaz-Manera J.

J Neurol Neurosurg Psychiatry. 2019 May;90(5):576-585. doi: 10.1136/jnnp-2018-319578. Epub 2018 Dec 8.

PMID:
30530568
12.

Regional variation of Guillain-Barré syndrome.

Doets AY, Verboon C, van den Berg B, Harbo T, Cornblath DR, Willison HJ, Islam Z, Attarian S, Barroso FA, Bateman K, Benedetti L, van den Bergh P, Casasnovas C, Cavaletti G, Chavada G, Claeys KG, Dardiotis E, Davidson A, van Doorn PA, Feasby TE, Galassi G, Gorson KC, Hartung HP, Hsieh ST, Hughes RAC, Illa I, Islam B, Kusunoki S, Kuwabara S, Lehmann HC, Miller JAL, Mohammad QD, Monges S, Nobile Orazio E, Pardo J, Pereon Y, Rinaldi S, Querol L, Reddel SW, Reisin RC, Shahrizaila N, Sindrup SH, Waqar W, Jacobs BC; IGOS Consortium.

Brain. 2018 Oct 1;141(10):2866-2877. doi: 10.1093/brain/awy232.

13.

Effect of MAPK Inhibition on the Differentiation of a Rhabdomyosarcoma Cell Line Combined With CRISPR/Cas9 Technology: An In Vitro Model of Human Muscle Diseases.

De Luna N, Suarez-Calvet X, Garicano M, Fernandez-Simon E, Rojas-García R, Diaz-Manera J, Querol L, Illa I, Gallardo E.

J Neuropathol Exp Neurol. 2018 Oct 1;77(10):964-972. doi: 10.1093/jnen/nly078.

PMID:
30184235
14.

Quantitative muscle MRI to follow up late onset Pompe patients: a prospective study.

Figueroa-Bonaparte S, Llauger J, Segovia S, Belmonte I, Pedrosa I, Montiel E, Montesinos P, Sánchez-González J, Alonso-Jiménez A, Gallardo E, Illa I; Spanish Pompe group, Díaz-Manera J.

Sci Rep. 2018 Jul 18;8(1):10898. doi: 10.1038/s41598-018-29170-7.

15.

A new mutation of the SCGA gene is the cause of a late onset mild phenotype limb girdle muscular dystrophy type 2D with axial involvement.

Gonzalez-Quereda L, Gallardo E, Töpf A, Alonso-Jimenez A, Straub V, Rodriguez MJ, Lleixa C, Illa I, Gallano P, Diaz-Manera J.

Neuromuscul Disord. 2018 Aug;28(8):633-638. doi: 10.1016/j.nmd.2018.06.002. Epub 2018 Jul 13.

PMID:
30007747
16.

Nintedanib decreases muscle fibrosis and improves muscle function in a murine model of dystrophinopathy.

Piñol-Jurado P, Suárez-Calvet X, Fernández-Simón E, Gallardo E, de la Oliva N, Martínez-Muriana A, Gómez-Gálvez P, Escudero LM, Pérez-Peiró M, Wollin L, de Luna N, Navarro X, Illa I, Díaz-Manera J.

Cell Death Dis. 2018 Jul 10;9(7):776. doi: 10.1038/s41419-018-0792-6.

17.

The impact of rituximab infusion protocol on the long-term outcome in anti-MuSK myasthenia gravis.

Cortés-Vicente E, Rojas-Garcia R, Díaz-Manera J, Querol L, Casasnovas C, Guerrero-Sola A, Muñoz-Blanco JL, Bárcena-Llona JE, Márquez-Infante C, Pardo J, Martínez-Fernández EM, Usón M, Oliva-Nacarino P, Sevilla T, Illa I.

Ann Clin Transl Neurol. 2018 Apr 14;5(6):710-716. doi: 10.1002/acn3.564. eCollection 2018 Jun.

18.

Distinct Clinical Features and Outcomes in Motor Neuron Disease Associated with Behavioural Variant Frontotemporal Dementia.

Cortés-Vicente E, Turon-Sans J, Gelpi E, Clarimón J, Borrego-Écija S, Dols-Icardo O, Illán-Gala I, Lleó A, Illa I, Blesa R, Al-Chalabi A, Rojas-García R.

Dement Geriatr Cogn Disord. 2018;45(3-4):220-231. doi: 10.1159/000488528. Epub 2018 Jun 8.

PMID:
29886477
19.

Antibodies against cell adhesion molecules and neural structures in paraneoplastic neuropathies.

Siles AM, Martínez-Hernández E, Araque J, Diaz-Manera J, Rojas-Garcia R, Gallardo E, Illa I, Graus F, Querol L.

Ann Clin Transl Neurol. 2018 Mar 26;5(5):559-569. doi: 10.1002/acn3.554. eCollection 2018 May.

20.

JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis.

Ladislau L, Suárez-Calvet X, Toquet S, Landon-Cardinal O, Amelin D, Depp M, Rodero MP, Hathazi D, Duffy D, Bondet V, Preusse C, Bienvenu B, Rozenberg F, Roos A, Benjamim CF, Gallardo E, Illa I, Mouly V, Stenzel W, Butler-Browne G, Benveniste O, Allenbach Y.

Brain. 2018 Jun 1;141(6):1609-1621. doi: 10.1093/brain/awy105.

PMID:
29741608
21.

Head and voice tremor improving with immunotherapy in an anti-NF155 positive CIDP patient.

Painous C, López-Pérez MÁ, Illa I, Querol L.

Ann Clin Transl Neurol. 2018 Mar 7;5(4):499-501. doi: 10.1002/acn3.539. eCollection 2018 Apr.

22.

Mcleod syndrome is a new cause of axial muscle weakness.

Díaz-Manera J, Sotoca-Fernández J, Alonso-Jiménez A, Marzo ME, Gallardo E, Segovia-Simón S, Siles AM, Illa I, Pagonabarraga J.

Muscle Nerve. 2018 Jan 30. doi: 10.1002/mus.26086. [Epub ahead of print] No abstract available.

PMID:
29381810
23.

Anti-NF155 chronic inflammatory demyelinating polyradiculoneuropathy strongly associates to HLA-DRB15.

Martinez-Martinez L, Lleixà MC, Boera-Carnicero G, Cortese A, Devaux J, Siles A, Rajabally Y, Martinez-Piñeiro A, Carvajal A, Pardo J, Delmont E, Attarian S, Diaz-Manera J, Callegari I, Marchioni E, Franciotta D, Benedetti L, Lauria G, de la Calle Martin O, Juárez C, Illa I, Querol L.

J Neuroinflammation. 2017 Nov 16;14(1):224. doi: 10.1186/s12974-017-0996-1.

24.

Antibodies against peripheral nerve antigens in chronic inflammatory demyelinating polyradiculoneuropathy.

Querol L, Siles AM, Alba-Rovira R, Jáuregui A, Devaux J, Faivre-Sarrailh C, Araque J, Rojas-Garcia R, Diaz-Manera J, Cortés-Vicente E, Nogales-Gadea G, Navas-Madroñal M, Gallardo E, Illa I.

Sci Rep. 2017 Oct 31;7(1):14411. doi: 10.1038/s41598-017-14853-4.

25.

Diagnostic utility of cortactin antibodies in myasthenia gravis.

Illa I, Cortés-Vicente E, Martínez MÁ, Gallardo E.

Ann N Y Acad Sci. 2018 Jan;1412(1):90-94. doi: 10.1111/nyas.13502. Epub 2017 Oct 25. Review.

PMID:
29068555
26.

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.

Howard JF Jr, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Muppidi S, Nowak RJ, O'Brien F, Wang JJ, Mantegazza R; REGAIN Study Group.

Lancet Neurol. 2017 Dec;16(12):976-986. doi: 10.1016/S1474-4422(17)30369-1. Epub 2017 Oct 20. Erratum in: Lancet Neurol. 2017 Dec;16(12 ):954.

PMID:
29066163
27.

ARTHUR ASBURY LECTURE: Chronic inflammatory demyelinating polyradiculoneuropathy: clinical aspects and new animal models of auto-immunity to nodal components.

Illa I.

J Peripher Nerv Syst. 2017 Dec;22(4):418-424. doi: 10.1111/jns.12237. Epub 2017 Nov 15. Review.

PMID:
29065233
28.

Hypoxia triggers IFN-I production in muscle: Implications in dermatomyositis.

De Luna N, Suárez-Calvet X, Lleixà C, Diaz-Manera J, Olivé M, Illa I, Gallardo E.

Sci Rep. 2017 Aug 17;7(1):8595. doi: 10.1038/s41598-017-09309-8.

29.

Distribution and genotype-phenotype correlation of GDAP1 mutations in Spain.

Sivera R, Frasquet M, Lupo V, García-Sobrino T, Blanco-Arias P, Pardo J, Fernández-Torrón R, de Munain AL, Márquez-Infante C, Villarreal L, Carbonell P, Rojas-García R, Segovia S, Illa I, Frongia AL, Nascimento A, Ortez C, García-Romero MDM, Pascual SI, Pelayo-Negro AL, Berciano J, Guerrero A, Casasnovas C, Camacho A, Esteban J, Chumillas MJ, Barreiro M, Díaz C, Palau F, Vílchez JJ, Espinós C, Sevilla T.

Sci Rep. 2017 Jul 27;7(1):6677. doi: 10.1038/s41598-017-06894-6.

30.

RIG-I expression in perifascicular myofibers is a reliable biomarker of dermatomyositis.

Suárez-Calvet X, Gallardo E, Pinal-Fernandez I, De Luna N, Lleixà C, Díaz-Manera J, Rojas-García R, Castellví I, Martínez MA, Grau JM, Selva-O'Callaghan A, Illa I.

Arthritis Res Ther. 2017 Jul 24;19(1):174. doi: 10.1186/s13075-017-1383-0.

31.

Autoantibodies in chronic inflammatory neuropathies: diagnostic and therapeutic implications.

Querol L, Devaux J, Rojas-Garcia R, Illa I.

Nat Rev Neurol. 2017 Sep;13(9):533-547. doi: 10.1038/nrneurol.2017.84. Epub 2017 Jul 14. Review.

PMID:
28708133
32.

Platelet-Derived Growth Factor BB Influences Muscle Regeneration in Duchenne Muscle Dystrophy.

Piñol-Jurado P, Gallardo E, de Luna N, Suárez-Calvet X, Sánchez-Riera C, Fernández-Simón E, Gomis C, Illa I, Díaz-Manera J.

Am J Pathol. 2017 Aug;187(8):1814-1827. doi: 10.1016/j.ajpath.2017.04.011. Epub 2017 Jun 12. Erratum in: Am J Pathol. 2018 Feb;188(2):539.

PMID:
28618254
33.

Autoantibodies to nodal isoforms of neurofascin in chronic inflammatory demyelinating polyneuropathy.

Delmont E, Manso C, Querol L, Cortese A, Berardinelli A, Lozza A, Belghazi M, Malissart P, Labauge P, Taieb G, Yuki N, Illa I, Attarian S, Devaux JJ.

Brain. 2017 Jul 1;140(7):1851-1858. doi: 10.1093/brain/awx124.

PMID:
28575198
34.

Early diagnosis of amyotrophic lateral sclerosis mimic syndromes: pros and cons of current clinical diagnostic criteria.

Cortés-Vicente E, Pradas J, Marín-Lahoz J, De Luna N, Clarimón J, Turon-Sans J, Gelpí E, Díaz-Manera J, Illa I, Rojas-Garcia R.

Amyotroph Lateral Scler Frontotemporal Degener. 2017 Aug;18(5-6):333-340. doi: 10.1080/21678421.2017.1316408. Epub 2017 Apr 25.

PMID:
28440098
35.

Bethlem Myopathy Phenotypes and Follow Up: Description of 8 Patients at the Mildest End of the Spectrum.

Cruz S, Figueroa-Bonaparte S, Gallardo E, de Becdelièvre A, Gartioux C, Allamand V, Piñol P, Garcia MA, Jiménez-Mallebriera C, Llauger J, González-Rodríguez L, Cortes-Vicente E, Illa I, Díaz-Manera J.

J Neuromuscul Dis. 2016 May 27;3(2):267-274.

PMID:
27854213
36.

Muscle MRI Findings in Childhood/Adult Onset Pompe Disease Correlate with Muscle Function.

Figueroa-Bonaparte S, Segovia S, Llauger J, Belmonte I, Pedrosa I, Alejaldre A, Mayos M, Suárez-Cuartín G, Gallardo E, Illa I, Díaz-Manera J; Spanish Pompe Study Group.

PLoS One. 2016 Oct 6;11(10):e0163493. doi: 10.1371/journal.pone.0163493. eCollection 2016.

37.

Clinical Characteristics of Patients With Double-Seronegative Myasthenia Gravis and Antibodies to Cortactin.

Cortés-Vicente E, Gallardo E, Martínez MÁ, Díaz-Manera J, Querol L, Rojas-García R, Illa I.

JAMA Neurol. 2016 Sep 1;73(9):1099-104. doi: 10.1001/jamaneurol.2016.2032.

PMID:
27379450
38.

International consensus guidance for management of myasthenia gravis: Executive summary.

Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I, Kuntz N, Massey JM, Melms A, Murai H, Nicolle M, Palace J, Richman DP, Verschuuren J, Narayanaswami P.

Neurology. 2016 Jul 26;87(4):419-25. doi: 10.1212/WNL.0000000000002790. Epub 2016 Jun 29. Review.

39.

Amyotrophic lateral sclerosis: A higher than expected incidence in people over 80 years of age.

Aragones JM, Altimiras J, Roura-Poch P, Homs E, Bajo L, Povedano M, Cortés-Vicente E, Illa I, Al-Chalabi A, Rojas-García R.

Amyotroph Lateral Scler Frontotemporal Degener. 2016 Oct - Nov;17(7-8):522-527. Epub 2016 May 25.

PMID:
27224687
40.

Muscle MRI in muscular dystrophies.

Díaz-Manera J, Llauger J, Gallardo E, Illa I.

Acta Myol. 2015 Dec;34(2-3):95-108.

41.

Contactin-1 IgG4 antibodies cause paranode dismantling and conduction defects.

Manso C, Querol L, Mekaouche M, Illa I, Devaux JJ.

Brain. 2016 Jun;139(Pt 6):1700-12. doi: 10.1093/brain/aww062. Epub 2016 Mar 26.

PMID:
27017186
42.

Longitudinal epitope mapping in MuSK myasthenia gravis: implications for disease severity.

Huijbers MG, Vink AF, Niks EH, Westhuis RH, van Zwet EW, de Meel RH, Rojas-García R, Díaz-Manera J, Kuks JB, Klooster R, Straasheijm K, Evoli A, Illa I, van der Maarel SM, Verschuuren JJ.

J Neuroimmunol. 2016 Feb 15;291:82-8. doi: 10.1016/j.jneuroim.2015.12.016. Epub 2016 Jan 5.

PMID:
26857500
43.

Transthyretin-related hereditary amyloid polyneuropathy presenting with large fibre involvement and cardiomyopathy.

Cruz S, Cortes-Vicente E, Illa I, Rojas-Garcia R.

Amyloid. 2016;23(1):64-5. doi: 10.3109/13506129.2015.1127223. Epub 2016 Jan 23. No abstract available.

PMID:
26806028
44.

Comment to "Role of Toll-like receptors and retinoic acid inducible gene I in endogenous production of type I interferon in dermatomyositis".

Suárez-Calvet X, Gallardo E, Illa I.

J Neuroimmunol. 2016 Feb 15;291:125. doi: 10.1016/j.jneuroim.2015.12.008. Epub 2015 Dec 18. No abstract available.

PMID:
26723487
45.

Muscle imaging in muscle dystrophies produced by mutations in the EMD and LMNA genes.

Díaz-Manera J, Alejaldre A, González L, Olivé M, Gómez-Andrés D, Muelas N, Vílchez JJ, Llauger J, Carbonell P, Márquez-Infante C, Fernández-Torrón R, Poza JJ, López de Munáin A, González-Quereda L, Mirabet S, Clarimon J, Gallano P, Rojas-García R, Gallardo E, Illa I.

Neuromuscul Disord. 2016 Jan;26(1):33-40. doi: 10.1016/j.nmd.2015.10.001. Epub 2015 Oct 22.

PMID:
26573435
46.

Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins.

Querol L, Rojas-García R, Diaz-Manera J, Barcena J, Pardo J, Ortega-Moreno A, Sedano MJ, Seró-Ballesteros L, Carvajal A, Ortiz N, Gallardo E, Illa I.

Neurol Neuroimmunol Neuroinflamm. 2015 Sep 3;2(5):e149. doi: 10.1212/NXI.0000000000000149. eCollection 2015 Oct.

47.

Allogeneic haematopoietic stem cell transplantation for mitochondrial neurogastrointestinal encephalomyopathy.

Halter JP, Michael W, Schüpbach M, Mandel H, Casali C, Orchard K, Collin M, Valcarcel D, Rovelli A, Filosto M, Dotti MT, Marotta G, Pintos G, Barba P, Accarino A, Ferra C, Illa I, Beguin Y, Bakker JA, Boelens JJ, de Coo IF, Fay K, Sue CM, Nachbaur D, Zoller H, Sobreira C, Pinto Simoes B, Hammans SR, Savage D, Martí R, Chinnery PF, Elhasid R, Gratwohl A, Hirano M.

Brain. 2015 Oct;138(Pt 10):2847-58. doi: 10.1093/brain/awv226. Epub 2015 Aug 10.

48.

Paranodal and other autoantibodies in chronic inflammatory neuropathies.

Querol L, Illa I.

Curr Opin Neurol. 2015 Oct;28(5):474-9. doi: 10.1097/WCO.0000000000000233. Review.

PMID:
26263474
49.

The expanding field of IgG4-mediated neurological autoimmune disorders.

Huijbers MG, Querol LA, Niks EH, Plomp JJ, van der Maarel SM, Graus F, Dalmau J, Illa I, Verschuuren JJ.

Eur J Neurol. 2015 Aug;22(8):1151-61. doi: 10.1111/ene.12758. Epub 2015 May 29. Review.

PMID:
26032110
50.

Targeted screening for the detection of Pompe disease in patients with unclassified limb-girdle muscular dystrophy or asymptomatic hyperCKemia using dried blood: A Spanish cohort.

Gutiérrez-Rivas E, Bautista J, Vílchez JJ, Muelas N, Díaz-Manera J, Illa I, Martínez-Arroyo A, Olivé M, Sanz I, Arpa J, Fernández-Torrón R, López de Munáin A, Jiménez L, Solera J, Lukacs Z.

Neuromuscul Disord. 2015 Jul;25(7):548-53. doi: 10.1016/j.nmd.2015.04.008. Epub 2015 Apr 23.

PMID:
25998610

Supplemental Content

Support Center